Compare Dropbox Inc (DBX) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Incyte Corporation — how do they compare? Dropbox Inc trades at $33.16 (market cap $7.41B), while Incyte Corporation trades at $120.02 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 3.3× Dropbox Inc's market cap. Which is the better fit depends on your goals.
| DBX | INCY | |
|---|---|---|
Market Cap | $7.41B | $24.54B |
Sector | Technology | Health |
52-Week High | $35.00 | $129.93 |
52-Week Low | $22.06 | $81.61 |
Enterprise Value | $10.27B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBX trades at $34.59, down 0.63% today, with a bullish technical signal from moving averages and recent earnings beats. Revenue remains steady at $2.52B for 2025, with a net income margin of 20.16%. The company raised its 2026 outlook after Q2 results, supported by core file-sync-and-share growth and AI expansion. Cash flow from operations improved to $952M in 2025, though net cash flow was negative due to financing activities.
The outlook is mixed; strong profitability and bullish analyst coverage contrast with high debt levels and negative shareholder equity. Risks include competitive pressures and reliance on sustained user growth. With 37.5% of analysts rating it a buy, the stock offers growth potential but requires monitoring of balance sheet health and execution risks.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
